Pharma & Bio
Technology
Samsung Bio and VUNO Fall on Rights Offerings…SHINPOONG and CHO-A Rise [K-Bio Pulse]
On August 28, major pharmaceutical and biotech companies saw mixed stock performances as investors reacted to various corporate developments.Samsung Biologics shares plunged 6.78% following the compan…
Technology
Samsung Bio and VUNO, Inc. Shares Plunge on Rights Offer… ShinpoongPharmaceutical and ChoA Pharmaceutical Co., LTD. Rise [Bio Roundup]
On the 28th, stock prices of major companies in the pharmaceutical and biotech sector showed divergent trends depending on various events. SAMSUNG BIOLOGICS(207940), which announced a large-scale righ…
Technology
ABION Inc. at 5.6 Months, ABL Reports Net Cash Inflow… “Financial Stamina” Determined by Technology Transfer
(Graphic: ChatGPT)
The financial health of domestically listed biotech companies is diverging sharply depending on their performance in technology transfers and commercialization. It is estimated t…
Lifestyle
Dasan Pharmaceutical Sets Sights on a “One-Shot Listing” on KOSDAQ… Taking a “Straightforward Approach” with a Stock Split and Enhanced Internal Controls
Dasan Pharmaceutical, a contract development and manufacturing organization (CDMO) specializing in pharmaceuticals that is celebrating its 30th anniversary, has completed all regulatory and managerial…
Lifestyle
VIVOZON PHARMACEUTICAL Signs Supply Contract in China; CG Invites’ mRNA Shares Rise... Huons Co., Ltd. Shares Up Following ‘Merger Withdrawal’ [Bio Market Watch]
On the 27th, the pharmaceutical and life sciences sectors showed mixed performance on the domestic stock market. The pharmaceutical sector declined, while the life sciences sector rose slightly.On tha…
Technology
Vivozon Expands in China... Huons Scraps Merger Plan [K-Bio Pulse]
On Aug. 27, South Korea’s pharmaceutical and life sciences sectors moved in opposite directions, with pharmaceutical stocks weakening while life sciences shares edged higher.The pharmaceutical sector …
Technology
CEO of Shangya Bio, a Partner of Xcell Therapeutics Inc.: “China’s Recombinant Collagen Skin Boosters Reach the ‘J’ Level… Changes Are Coming to Korea, Too”
“The center of gravity in China’s medical beauty market is already shifting from hyaluronic acid (HA) to recombinant collagen. I believe the same shift will begin in South Korea as well.”Liu Yang, Gen…
Technology
[PharmaResearch Deep Dive ②] Growth Rates for Rejuran and Others Plunge from 93.5% to 6.2%... Monopoly Premium at Risk of Disappearing
PharmaResearch(214450) The growth rate of domestic sales of medical devices (including Rejuran and Conjuran) plummeted from 93.5% to 6.2% for the first time in five quarters. The industry views this a…
Lifestyle
[Exclusive] Ingenia Claims to Have Secured a Long-Term Shareholding Commitment from FI… Will Overhang Concerns Ease?
“Key executives at Ingenia Therapeutics recently met with major financial investors (FIs), including Intervest and Aurum Asset Management, and secured commitments to hold their stakes in the company f…
Lifestyle
OscoTech Integrates Struggling Subsidiary Genosco… Shareholders and Board Face Complex Calculations
It has been about six months since Oskotec announced its plan to make its subsidiary Genosco a wholly-owned subsidiary, but key preliminary procedures—such as the establishment of a special committee …